Adis has taken a major step forward in its quest to make expertly-written drug information more accessible, with the launch of a new platform.
AdisInsight presents a unique, joined-up view of current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available – in a single database.
All of the content in the platform is created as a result of a rigorous curation process undertaken by a team of scientific editors. Multiple global sources including journals, conference proceedings, government and company websites are monitored continuously to identify any potentially relevant new data. Information is then assessed and verified before being consolidated into concise narratives.
Mike Sumner, Director of Product Management for AdisInsight, explains:
“We know that many people access drug information – from academics to regulators, investors to healthcare providers and of course, pharmaceutical manufacturers. These groups may use the information in different ways but they all share a common need – to quickly and easily find accurate data to answer their questions. The AdisInsight platform is designed to help them do just that.”
Adis is a leading global provider of drug information and part of Springer Science+Business Media. For more than 40 years Adis has been supporting its users through its portfolio of drug-focused medical journals and business intelligence solutions. AdisInsight brings together content from three well-established Adis databases – R&D Insight, Clinical Trials Insight and Pharmacovigilance Insight. The AdisInsight platform is available to preview now at adisinsight.springer.com